PMID: 16529340Mar 15, 2006Paper

Exenatide: from the Gila monster to the pharmacy

Journal of the American Pharmacists Association : JAPhA
Curtis Triplitt, Elaine Chiquette

Abstract

To explain the incretin concept and review the pharmacology and clinical utility of exenatide (Byetta-Amylin; Lilly), a new agent for the treatment of patients with type 2 diabetes mellitus, and provide pharmacists with information necessary for counseling patients in the use of exenatide. Review articles, clinical trials, and data on file with the manufacturers. By the authors. By the authors. Exenatide is a synthetic form of a protein found in the saliva of the Gila monster that mimics the action of glucagon-like peptide-1, an incretin important in glucose homeostasis and deficient in patients with diabetes mellitus. Three pivotal clinical trials of exenatide as an add-on therapy in patients with type 2 diabetes mellitus who were unable to achieve glycemic control with maximum doses of metformin, sulfonylurea, or these drugs in combination demonstrated significant reductions in glycosylated hemoglobin (A1C) levels following twice-daily self-injection of exenatide compared with placebo. Weight loss was observed in patients in conjunction with A1C improvement, which occurred without additional patient instruction, intentional caloric deficit, or exercise. Mild-to-moderate nausea was the most common adverse event with exenatide ...Continue Reading

References

May 1, 1992·Molecular and Cellular Endocrinology·H C FehmannB Göke
May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·D J DruckerJ F Habener
Jan 1, 1986·Diabetologia·M NauckW Creutzfeldt
Jun 1, 1969·The American Journal of the Medical Sciences·E Aguilar-ParadaR H Unger
Apr 1, 1970·The Journal of Clinical Investigation·R H UngerA M Eisentraut
Feb 1, 1995·Acta Physiologica Scandinavica·B Ahrén
Oct 22, 1998·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·B Ahrén
Sep 8, 2000·Diabetes Care·A H MokdadJ S Marks
Oct 4, 2000·JAMA : the Journal of the American Medical Association·A H MokdadJ P Koplan
Aug 15, 2001·The Journal of Clinical Endocrinology and Metabolism·M B Toft-NielsenJ J Holst
Sep 11, 2001·The Journal of Clinical Endocrinology and Metabolism·C VerdichA Astrup
Sep 18, 2001·JAMA : the Journal of the American Medical Association·A H MokdadJ P Koplan
Oct 13, 2001·The Journal of Biological Chemistry·Y KashimaS Seino
Sep 17, 2003·Current Diabetes Reports·Bo Ahrén
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Sharon H SaydahCatherine C Cowie
Jul 24, 2004·American Journal of Physiology. Endocrinology and Metabolism·Jens Juul Holst, Jesper Gromada
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Aug 16, 2005·Journal of Clinical Pharmacology·Prajakti A KothareStephen D Wise
Sep 8, 2005·The Journal of Clinical Endocrinology and Metabolism·Frauke FehseMichael A Nauck

❮ Previous
Next ❯

Citations

Oct 6, 2010·Genome Biology·Camilla M WhittingtonWesley C Warren
Sep 17, 2013·Drug Design, Development and Therapy·Yunpeng CaiWeien Yuan
Feb 28, 2013·Journal of Clinical Pharmacy and Therapeutics·Susan A Cornell
Feb 2, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Michael E MinshallAndrew J Palmer
Nov 1, 2018·Current Medicinal Chemistry·Xinwang YangEng-Ang Ling
Mar 13, 2018·Frontiers in Pharmacology·Jessica M de SouzaFabiola M Ribeiro
Jan 24, 2020·Biophysical Journal·Anja StulzHeiko Heerklotz
Jun 15, 2020·Biochemical Pharmacology·Volker HerzigGlenn F King

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.